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AbstrACt
Objectives To assess the psychometric properties of the 
short form of The Problem Areas in Diabetes scale (PAID-5) 
in Norwegian adult patients with type 1 or type 2 diabetes.
Design Cross-sectional survey design.
Methods Participants (n=143) were included from 
three Western-Norway endocrinology outpatient clinics. 
Demographic and clinical data were collected in addition 
to questionnaires concerning diabetes-related distress, 
fear of hypoglycaemia, symptoms of depression, emotional 
well-being and perception of general health. Psychometric 
evaluation of the PAID-5 included confirming its postulated 
one-factor structure using confirmatory factor analysis 
(CFA) and assessing convergent validity, discriminant 
validity, internal consistency and test-retest reliability. The 
retest questionnaire was sent out 35±15 days after the 
initial assessment to those who agreed (n=117).
results The CFA for the PAID-5 scale showed excellent 
one-factor structure, and there was high internal 
consistency (α=0.89) and good test-retest reliability 
(Intraclass Correlation Coefficient, ICC=0.81). The PAID-5 
correlated positively with fear of hypoglycaemia (r=0.598) 
and depression (r=0.380) and negatively with emotional 
well-being (r=−0.363) and perception of general health 
(r=−0.420), thus satisfying convergent validity. Patients 
who had experienced episodes of serious hypoglycaemia 
in the past 6 months had a significantly higher PAID-5 
mean score (7.5, SD=4.95) than those who had not had 
these episodes (5.0, SD=4.2 (p=0.043)).
Conclusion The Norwegian PAID-5 was shown to be 
a reliable and valid short questionnaire for assessing 
diabetes-related distress among people with type 1 or type 
2 diabetes. However, its ability to discriminate between 
groups needs to be tested further in larger samples. The 
PAID-5 scale can be a particularly valuable screening 
instrument in outpatient clinics, as its brevity makes it easy 
to use as a tool in patient-provider encounters. This short 
questionnaire is useful in the national diabetes registry 
or population cohort studies as it enables increased 
knowledge regarding the prevalence of diabetes-related 
distress.
IntrODuCtIOn
The International Diabetes Federation1 states 
that diabetes is one of the largest global health 
emergencies of the 21st century and that 
by the year 2045 an estimated 628.6 million 
people will have diabetes, which is 9.9% 
of the total world population. In Norway, 
the prevalence of type 2 diabetes increased 
from 4.9% to 6.1% between 2009 and 2014.2 
After Finland and Sweden, Norway is among 
the countries with the highest incidence of 
childhood-onset type 1 diabetes in the world 
and the average incidence rate was 32.7 per 
100 000 person-years from 2004 to 2012.3 The 
Diabetes Control and Complications Trial 
showed that inadequate quality of diabetes 
care contributes to an increased risk for 
developing a number of serious and disabling 
health problems among people with type 1 
diabetes.4 The United Kingdom Prospective 
Diabetes Study showed similar results among 
people with type 2 diabetes.5 
The daily demands of diabetes, as a chronic 
disease, have a negative impact on phys-
ical health and on psychological health.6 
The complex nature of diabetes itself, acute 
fluctuations in blood glucose levels and the 
fear of long-term complications lead to high 
levels of subclinical diabetes-specific distress.7 
Diabetes distress is part of the experience of 
diabetes for many patients over time.8 9 Even 
strengths and limitations of this study
 ► The Norwegian Problem Areas in Diabetes 
scale  (PAID-5) demonstrated good psychometric 
properties, enabling the assessment of diabetes-re-
lated emotional distress.
 ► The non-responders were younger than the partici-
pants, which calls for caution when interpreting the 
results for younger adults with diabetes.
 ► The sample size restricted us in determining if the 
PAID-5 scale has the ability to discriminate between 
different subgroups.
 ► Further testing in a larger sample is required.
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at low levels, diabetes distress has been shown to be related 
to glycaemic control and behavioural management.8 10 
People with diabetes make far more health management 
decisions compared with healthcare personnel, and the 
needs of the person with diabetes including attention 
to emotional distress must be addressed in the clinical 
setting.11
The cross-national Diabetes Attitudes, Wishes and 
Needs (DAWN) study showed that almost half of the study 
population had a high level of diabetes-related distress.6 
High levels of diabetes-related distress have been linked 
to medication non-adherence, higher HbA1c, lower 
self-efficacy and poor dietary and exercise behaviours 
that lead to poor health outcomes.12 Screening for diabe-
tes-specific distress is important in a clinical setting and 
has been recommended at key time points in the care 
pathway such as diagnosis, annual medical appointments 
and inpatient episodes, when complications arise and 
when issues of glycaemic control or self-management 
arise.13 Therefore, healthcare personnel need to have 
validated tools to assess patients’ perceived diabetes-spe-
cific distress.
The PAID-20 is a valid 20-item scale to measure the 
overall level of diabetes-related emotional distress, devel-
oped in the USA.14 Each item represents a unique area 
of diabetes-related psychological stress and higher scores 
indicate greater emotional diabetes-related distress. The 
validation study of the PAID-20 questionnaire conducted 
in Norway showed sufficient reliability and validity among 
adults with type 1 and type 2 diabetes.15 A shorter version 
of the PAID, which has five items (The Problem Areas in 
Diabetes scale (PAID-5)), was developed as a tool that can 
be used for rapid screening of diabetes-related distress both 
in a clinical setting and in research studies.16 The brevity 
of the PAID-5 may impose a lower burden on patients with 
diabetes and represents efforts to increase the clinical 
usefulness of the original scale17 as the length and unclear 
factor structure of the PAID-20 have been identified as 
shortcomings.17 18 The PAID-5 has been validated among 
people with type 2 diabetes in Korea19 and among people 
with type 1 and type 2 diabetes in the multicultural DAWN 
study.16 In both studies, the PAID-5 showed good reliability 
and validity.16 19 As research concerning diabetes and the 
associated psychological burden continues to receive more 
attention from researchers, healthcare providers and 
patients, the availability of sound instruments is important 
for screening, and to compare different cultures and 
populations on a global basis. However, a questionnaire 
that is not properly translated and culturally adapted will 
be a threat to validity and reliability. Empirical testing of 
validity and reliability should follow the translation and 
cultural adaptation phase.20 There is still limited knowl-
edge of the psychometric properties of the PAID-5 scale 
in Europe, in particular the factor structure of the PAID-
5.16 17 19 As there is a need for a short diabetes distress ques-
tionnaire in the Norwegian Diabetes Registry for Adults as 
well as in population based cohort studies, this needs to 
be explored.
Aim
The aim of this study was to examine the psychometric 
properties of the PAID-5 scale. We hypothesised that 
PAID-5 scores would be positively associated with worry 
about hypoglycaemia and symptoms of depression, as 
variants of the same construct, and negatively associated 
with the perception of general health and emotional well-
being. The associations between PAID-5 scores and demo-
graphic (age, gender) and clinical variables (HbA1c, 
duration of diabetes, insulin therapy, diabetes-related 
complications and episodes of serious hypoglycaemia) 
were examined. We hypothesised that the PAID-5 scores 
would discriminate between diabetes-related emotional 
distress at a group level for gender, insulin regimen and 
presence of diabetes long-term complications. The reli-
ability of the PAID-5 scale was examined by its internal 
consistency and test-retest reliability. We also tested the 
unidimensionality of the PAID-5 questionnaire.
MethODs
Design, sample and setting
A cross-sectional survey design was used to collect data 
from three Western-Norway endocrinology outpatient 
clinics between October 2016 and March 2017 by using 
a consecutive sampling strategy. According to a Monte-
Carlo simulation study on estimation of sample size for 
confirmatory factor analysis (CFA), 190 cases are required 
for a one-factor model with four items and standardised 
loadings equal to 0.5, while a model with six items and 
the same loadings requires a sample size of 90.21 Given 
that the PAID-5 has five items, the minimum required 
sample size in our study was determined to be between 
90 and 190. We included more participants than needed 
based on the power analysis, because of the possibility for 
a low response rate. Therefore, 341 patients who met the 
inclusion criteria were invited to participate in the study. 
Patients were considered eligible for participation if they 
were diagnosed with type 1 or type 2 diabetes more than 
1 year ago, were between 18 and 65 years old, had the 
mental capacity to participate and were able to read and 
write in Norwegian language. We included only patients 
diagnosed with type 1 or type 2 diabetes more than 1 year 
ago, as patients may have more diabetes distress adapting 
to living with diabetes in the first year. Patients with gesta-
tional diabetes, short life expectancy or terminal illness 
and patients who were not able to give informed consent 
due to some serious mental illness or cognitive disorder 
were excluded.
Data collection procedure
Patients meeting the inclusion criteria received the ques-
tionnaire (68 questions in total) by mail, an information 
letter, a consent form to accept, prepaid envelopes and 
stamps. To examine the stability of the PAID-5 measure-
ment, the retest questionnaire was sent out 35±15 days 
after the first assessment to those who agreed (n=117).
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Measures
The questionnaire included questions on demographic 
and clinical characteristics: age, gender, duration of 
diabetes, diabetes treatment (using insulin and/or oral 
glucose-lowering agents), episodes of serious hypogly-
caemia (needing help from others) in the last 6 months, 
and the presence of diabetes long-term complications 
(cardiovascular diseases, retinopathy and foot ulcers). 
The most recent HbA1c, taken in close connection to the 
data collection, was obtained from medical records, as a 
measure of metabolic control. HbA1c values older than 8 
weeks prior and more than 12 weeks after filling out the 
survey were excluded.
The questionnaire included the overall question of 
the RAND-36 scale to assess perceptions of general 
health (‘In general, how would you say your health is?’). 
Responses were rated on a Likert scale from 1 (excellent) 
to 5 (poor). Higher scores indicate poorer health.22
The HAD-scale is a measure for screening symptoms 
of anxiety and depression.23 In the current study, we 
used only the HADS-D scale with seven self-report items 
measuring general symptoms of depression. Responses 
are rated on a 4-point Likert scale from 0 (not a problem) 
to 3 (a serious problem). Higher scores indicate higher 
levels of depressive symptoms. According to Bjelland et 
al,24 the validity of the HAD scale generally has been good 
to very good. The Norwegian version of the HAD-scale 
has shown good psychometric properties in terms of its 
two-factor structure, intercorrelation of the subscales 
(variance of 24%–36%) and internal consistency 
(α=0.73–0.85).25
The WHO-5 questionnaire monitors a person’s level 
of emotional well-being. This generic unidimensional 
instrument includes five positively worded items, rated 
on a 6-point Likert scale. Higher scores indicate better 
well-being. The WHO-5 questionnaire has been shown to 
be a psychometrically sound instrument among patients 
with type 1 and type 2 diabetes in terms of its one-factor 
structure, interitem correlations (0.71–0.84) and internal 
consistency (α=0.91 and 0.93).26 27
The Hypoglycemia Fear Survey II (HFS-II) has two 
subscales (33 items), one measuring worry about hypo-
glycaemia and its negative effects (HFS-W) and the other 
one behaviour to avoid hypoglycaemia (HFS-B).28 In this 
study, only the HFS-W (18 items) was used, as the HFS-B 
has shown a questionable structure.29 The responses are 
rated on a 5-point Likert scale from 0 (never) to 4 (always), 
with higher scores indicating higher levels of fear related 
to hypoglycaemia. Internal consistency for the worry scale 
was satisfactory with a Cronbach’s α of 0.87.30
The PAID-20 questionnaire provides a total score from 
0 to 100, by summing the 0–4 responses given for each 
of the 20 items and multiplying this sum by 1.25.29 The 
PAID-5 contains questions 3, 6, 12, 16 and 19 from the full 
PAID-20 scale. The scale gives a total score from 0 to 20. A 
score of 8 and above indicates a high level of diabetes-re-
lated distress16 (online supplementary table S1).
Data analysis
Descriptive statistics were conducted to describe the 
sample. A CFA with maximum likelihood estimation was 
used to investigate the factor structure of the PAID-5 scale. 
Missing data for PAID-5 were handled by listwise deletion 
in CFA-models; however, only two persons had missing 
data on at least one item. Model fit was evaluated by 
inspection of various goodness-of-fit measures, including 
model χ2, df and associated p values. In addition, a good-
ness-of-fit index (GFI), comparative fit index (CFI), root 
mean squared error of approximation (RMSEA) and 
standardised root mean square residual (SRMR), ratio 
of χ²  value to the df (CMIN/DF) and normed fit index 
(NFI) were assessed.30 31 The model was considered to 
fit the data when the following criteria were satisfied: 
RMSEA<0.08, CFI>0.95, GFI>0.90, SRMR <0.08, CMIN/
DF<3, NFI>0.95.31 32
Convergent validity was assessed by Pearson’s correla-
tions33 to examine the relationships between diabetes-re-
lated emotional distress (PAID-5 scores) and perceived 
overall health, emotional well-being (WHO-5), depression 
(HADS-D) and worry about hypoglycaemia (HFS-W). We 
also investigated how the PAID-5 scale correlated with the 
total PAID-20 score. Coefficients in the range of 0–0.19 
were regarded as very weak, 0.2–0.39 as weak, 0.40–0.59 
as moderate, 0.6–0.79 as strong and 0.8–1 as very strong 
correlation.33 Discriminant validity assessed whether 
the PAID-5 scale can differentiate between groups. 
Independent samples t-tests were used to compare the 
mean scores on the PAID-5 for people with and without 
diabetes long-term complications and between type 1 
and type 2 diabetes. Relationships between the PAID-5 
score and age, diabetes duration, treatment regimen and 
metabolic control (HbA1c) were explored using Pearson 
correlations.
The reliability of the PAID-5 scale was estimated by 
calculating the internal consistency and the test-retest 
reliability. Cronbach’s α was used to determine internal 
consistency for the PAID-5 scale total scores. Test-retest 
reliability for the PAID-5 scale was examined by intraclass 
correlation coefficient.34
Missing substitution with the mean was used for the 
HAD depression scale when at least 5 items of 7 were 
answered.25 For all other questionnaires, when less than 
50% was missing, missing data were replaced with the 
case mean.35 Statistical Package for the Social Sciences 
(SPSS) V.23.0 and AMOS V.23.0 for Windows were used 
to analyse the data. A significance level of 0.05 was used 
in all analyses.
ethical considerations
The National Committee for Medical and Health 
Research Ethics assessed the application (2016/1104/
REK vest) and approval was obtained from the Norwegian 
Center for Research Data (ref. nr. 49383). In addition, 
approval was obtained from the clinics where the study 
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Patient and public involvement
Patients and or public were not involved in setting the 
research questions or planning the study. Outcomes were 
self-reported by patients based on predefined questions. 
The study had no patient advisers. Due to the nature of 
this validation study, feedback regarding the results was 
not planned for those involved.
results
Demographic and clinical data
The questionnaire was returned by 143 patients of 342 
yielding a response rate of 42%. Clinical and demo-
graphic characteristics are presented in table 1. The mean 
age of the participants was 48.9 years (SD 11.9) (range 
19–65). The mean HbA1c for the participants was 7.6% 
(60 mmol/mol) (SD 1.2). The mean duration of diabetes 
was 17.9 years (SD 12.9) (range 1–54 years). In total, 117 
patients (82%) agreed to the second assessment. The 
non-participants (n=197) were younger than the partic-
ipants (mean age 45.2 vs 48.9, p=0.006), and a larger 
proportion was male compared with the participants. The 
mean score for the PAID-5 in this study sample was 5.3 
(SD=4.3) and individual scores ranged from 0 to 19.
Validity
Construct validity
A CFA for PAID-5 was carried out for 141 patients 
(table 2). We hypothesised a one-factor model for 
PAID-5. After allowing the correlation between error 
terms between items 3 and 16, the overall χ2=6.0, df=4 
(p value of 0.195), showed a good model fit. Additional 
indices resulted as follows: RMSEA=0.061, CFI=0.995, 
GFI=0.984 and SRMR=0.024, NFI=0.984, CMIN/DF=1.51, 
showing excellent fit.
Convergent and discriminant validity
There was a significant moderate correlation between 
the PAID-5 total score and HFS worry scale (r=0.598, 
p<0.001). There was also a weak positive correla-
tion between the PAID-5 scale and HAD depression 
scale (r=0.380, p<0.001). Convergent validity was also 
confirmed by a negative correlation between the PAID-5 
and WHO-5 scale (r=−0.363, p<0.001) and the perception 
of general health (r=−0.420, p<0.001). The PAID-5 total 
score also correlated significantly with the PAID-20 total 
score (r=0.923, p<0.001).
There was no significant difference in PAID-5 scores 
between persons with type 1 diabetes (mean=5.59, 






  Age (years), mean±SD 48.9±11.9
  Male sex 78 (54.5)
Clinical variables
  Type of diabetes
   Type 1 87 (60.8)
   Type 2 56 (39.2)
  HbA1c (%), mean±SD*† 7.6±1.2
  HbA1c (mmol/mol), mean±SD*† 60±13
  Diabetes duration (years), mean±SD 17.1±12.9
  Type of treatment
   Insulin 88 (61.5)
   Oral medication 28 (19.6)
   Insulin and oral medication 27 (18.9)
  Episodes of serious hypoglycaemia
   1–3 times in the past 6 months 16 (11.2)
  Self-reported complications
  Presence of one or more late 
complications‡
32 (22.4)
Data are shown as n (%). Per cent of patients with valid values for 
categorical variables and mean±SD for continuous variables.
*HbA1c (glycated haemoglobin) measurements were reported using 
the International Federation of Clinical Chemistry units (mmol/mol) 
in addition to the derived NGSP units (%).
†n=100, HbA1c values older than 8 weeks a prior and more than 12 
weeks after filling out the survey were excluded.
‡Retinopathy, cardiovascular diseases or foot ulcers.
Table 2 Factor loadings and goodness-of-fit indices for the 
PAID-5 one-factor solutions
Model 1 Model 2
Standardised loadings
  Item 3 0.83 0.85
  Item 6 0.86 0.85
  Item 12 0.82 0.80
  Item 16 0.68 0.72
  Item 19 0.73 0.72
AVE 0.62 0.63
Composite reliability 0.76 0.76
Df 5 4







Model 1: One-factor CFA, Model 2: One-factor CFA with 
covariance of error terms between item 3 and 16.
χ2 (p): Model χ2. CFI: comparative fit index (good fit >0.95). GFI: 
goodness of fit index (good fit >0.90); SRMR: standardised root 
mean square residual (good fit <0.08). RMSEA: root mean square 
error of approximation (acceptable fit <0.08); CMIN/DF: ratio of χ2 
value to the df (<3); NFI: normed fit index (good fit >0.95).
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SD=4.58) and persons with type 2 diabetes (mean=4.95, 
SD=3.93, p=0.38). There was also no significant differ-
ence in PAID-5 mean scores between those who reported 
having diabetes long-term complications (mean=5.75, 
SD=0.7) and those not having these complications 
(mean=5.2, SD=4.4, t(140)=0.61, p=0.54). Diabetes-re-
lated distress mean scores approached statistical signif-
icance when comparing patients who reported having 
retinopathy (7.2, SD=4.0) versus those without retinop-
athy (mean=5.1, SD=4.2, p=0.06). Although women 
scored higher on the PAID-5 (mean=5.9, SD=4.6) than 
men (mean=4.86, SD=4.01), the difference was not signif-
icant (p=0.15).
Patients who had experienced episodes of serious 
hypoglycaemia in the past 6 months had a significantly 
higher PAID-5 mean score (7.5 (SD=4.95)) versus those 
who had not had these episodes (5.0, SD=4.2 (p=0.043)). 
There were no significant differences in the PAID-5 mean 
scores for the three different treatment groups: insulin 
(n=87), oral medication (n=28) or both (n=27) (p=0.90). 
There were no significant correlations with higher age 
and longer duration of diabetes. Higher HbA1c was posi-
tively correlated with higher PAID-5 mean scores, but 
the correlation was weak (r=0.14) and not significant 
(p=0.16).
reliability
Internal consistency and test-retest reliability
The Cronbach’s α for the PAID-5 scale was 0.89. Inter—
item correlations for the PAID-5 scale ranged from 0.49 to 
0.74. The test-retest reliability of the PAID-5 was assessed in 
92 participants who returned the repeat questionnaire and 
resulted in an ICC of 0.81 (95% CI 0.70 to 0.87, p<0.001).
DIsCussIOn
The results of the current study demonstrate satisfac-
tory psychometric properties of the short form of the 
PAID-5 in Norwegian adult patients with type 1 and type 2 
diabetes. Our findings provide evidence for a one-factor 
structure for the PAID-5 scale, enabling the assessment of 
diabetes-related emotional distress. Convergent validity 
was demonstrated by statistically significant moderate 
correlations with other concept-related PROMs. The 
PAID-5 scale showed good internal consistency and a 
stable test-retest reliability among patients with type 1 and 
type 2 diabetes across three different clinics in Norway. 
The instrument might be considered as a supplement to 
guide consultations or as a screening instrument in regis-
tries and/or population health databases. Use of this tool 
may increase knowledge on the prevalence of diabetes-re-
lated emotional distress and thus inform guidelines for 
healthcare professionals and future interventions.
The Norwegian version of the PAID-5 clearly demon-
strated a one-factor structure as postulated. The psycho-
metric results in the current study lend support to 
findings from two previous validation studies on the 
PAID-5 scale.16 19 In Asia, the Korean version of the 
PAID-5 enabled a one factor model and demonstrated 
excellent goodness-of-fit indices after the modification 
with the error of terms between items 3 and 6.17 Our 
CFA among Norwegians showed excellent goodness-of-fit 
indices after model modification with the covariance of 
error terms between items 3 and 16. Therefore, it seems 
that the instrument enables the assessment of diabetes-re-
lated emotional distress, although one data driven modi-
fication was needed that may have inflated the model fit.
The present study showed that the PAID-5 correlated 
positively with fear of hypoglycaemia (HFS) and symptoms 
of depression (HADS-D) and negatively with emotional 
well-being (WHO-5) and ones’ general health perception 
(RAND-36), which emphasises good convergent validity. 
When diabetes-related stress increases, emotional well-
being and perception of ones´ general health decreases, 
as expected.16 26 27 Previously, McGuire et al16 demonstrated 
the relationship between the PAID-5 scale and the WHO-5 
scale. However, there is limited evidence showing relation-
ships with concepts of fear of hypoglycaemia and symptoms 
of depression. We demonstrated this in the current study, 
emphasising the usefulness of this brief questionnaire.
The PAID-5 scale discriminates well among those who 
had experienced episodes of serious hypoglycaemia in the 
past 6 months compared with those who had not had hypo-
glycaemia. The study population in general experienced 
a low level of diabetes-related emotional distress, as the 
mean score on the PAID-5 for the study population was 5.3 
(SD=4.3). However, individual scores ranged from 0 to 19, 
indicating that there were patients with a high level of diabe-
tes-related emotional distress. Relationships between the 
PAID-5 scale and other subgroups were weak and non-sig-
nificant. For example, women scored higher on the PAID-5 
scale as expected, but this difference was not significant, 
probably due to the relatively small sample size as in the 
previous study conducted in Iceland.36 There were no signif-
icant differences between the mean PAID-5 scores for the 
three different treatment groups (insulin, oral medication 
or both) (p=0.90). Our relatively small sample size might be 
the reason, but it is also possible that type of treatment is 
not the main reason for a higher burden of diabetes distress. 
On the other hand, a higher HbA1c (as a measure of meta-
bolic control) might be a better marker as higher HbA1c 
was positively correlated with PAID-5 mean scores in this 
study (NS) as well as in previous research.15 However, future 
studies specifically designed to answer these questions (eg, 
by use of stratified sampling or by using latent class analyses) 
with large sample sizes are needed to test for discrimination 
between different subgroups.
In the current study, the mean diabetes duration of the 
study population was 17.1 years and metabolic control 
was generally close to the treatment goals, as 50% of the 
participants in the subgroup had a HbA1c value of ≤7.3% 
(56 mmol/mol). In the current study, the PAID-5 scale 
did not discriminate between groups, such as patients 
with and without diabetes-related long-term complica-
tions. This might be a consequence of the relatively low 
number of people with complications. Nevertheless, the 
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proportion of diabetes long-term complications seems 
reasonable for this patient group and is in line with 
previous research in Norway.15 37
Metabolic control (HbA1c measurements) was posi-
tively, but only weakly correlated with PAID-5. This is 
consistent with results from PAID-20 validation studies, 
where diabetes-related emotional distress and glycaemic 
control have shown to be positively correlated—as diabetes 
distress increases, HbA1c level also increases.15 38–40 
Although higher HbA1c values have been associated with 
high diabetes-related emotional distress, it should not be 
taken as self-evident that patients who are able to main-
tain an optimum blood sugar feel less distressed.
The short-form of the PAID-20, the PAID-5, showed a 
good internal consistency and test-retest reliability. This 
confirms the assumption in previous validation studies that 
the number of items in the PAID-20 could be reduced.15 Our 
findings and previous studies of the PAID-5 scale demon-
strated good to excellent internal consistency reliability, with 
Cronbach’s α varying from 0.83 to 0.93.6 16 19 41
Diabetes, which is a chronic disease, not only involves 
making healthy choices in one’s everyday life, but one 
must also have the ability to see diabetes and its psycho-
logical aspects as a larger and more complex picture 
with many different challenges throughout life. Diabetes 
self-management training is closely connected to how 
patients understand the nature of the disease and its 
management, thus reducing different fears (eg, fear of 
hypoglycaemia), guilt and frustration and at the same 
time increasing skills in managing diabetes self-care and 
medication adherence.7
strengths and limitations
In this well-defined sample of patients across three clinics, 
the Norwegian PAID-5 was shown to be a reliable and 
valid short questionnaire for assessing diabetes-related 
distress among people with type 1 or type 2 diabetes. 
Although the scale has demonstrated good psychometric 
properties, this study has limitations. Type of diabetes 
and metabolic control (HbA1c) were received from the 
patient’s medical record. However, other clinical charac-
teristics such as diabetes complications were self-reported 
by the patient, which may cause inaccuracies.33 Second, 
the non-responders were younger than the participants, 
which calls for caution when interpreting the results for 
younger adults with diabetes. Third, the information 
about the study and the request for participation was sent 
by mail. The distribution method in this study has prob-
ably contributed to a relatively low response rate. However, 
we had enough power to investigate the one-dimensional 
scale structure with a CFA. Nevertheless, the sample 
size restricted us in determining if the PAID-5 scale has 
the ability to discriminate between different subgroups. 
This needs further research in a larger sample. In spite 
of these limitations, this cross-sectional study provides a 
valid assessment of the psychometric properties of the 
short form of the PAID scale in Norwegian adult patients 
with type 1 and type 2 diabetes.
COnClusIOn
In conclusion, the findings from this study provide 
evidence that the Norwegian version of the PAID-5 scale 
is a reliable and valid instrument for assessing diabe-
tes-related emotional distress among patients with type 
1 and type 2 diabetes in Norway, although its ability to 
discriminate between groups needs to be tested further in 
a larger sample. The scale has only five items and has the 
potential to guide communication in one-on-one consul-
tations. Although this validation study was conducted 
among patients visiting their doctor or a diabetes nurse 
in specialty healthcare, the PAID-5 questionnaire is also 
relevant to use in primary healthcare.
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